Wordt geladen...
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninety-nine patients with high-risk neuroblastoma recei...
Bewaard in:
| Gepubliceerd in: | Front Pediatr |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7772209/ https://ncbi.nlm.nih.gov/pubmed/33392114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fped.2020.582820 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|